CBL-514 Enters Phase 3 Trials After Phase 2 Data Shows 12% Visceral Fat Reduction
CBL-514, a new injectable weight-loss drug, has entered Phase 3 clinical trials after Phase 2 results demonstrated significant reductions in visceral and subcutaneous fat. Unlike GLP-1 agonists that suppress appetite, CBL-514 induces apoptosis in fat cells, potentially offering a more permanent solution to weight regain. Early data shows a 12% drop in visceral fat within four weeks, with effects persisting after treatment cessation.
